[12] Patent
[11] Patent No.:GC0004556  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/89992
Date of the Decision to Grant the Patent:22/Dec/2016

[21] Application No.:GC 2012-22447

[22] Filing Date:3/10/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
7/10/2011
24/10/2011
10/11/2011
61/544,860
61/550,623
61/558,110

[72] Inventors:1- Yoshihiko NORIMINE،2- Kunitoshi TAKEDA،3- Koji HAGIWARA،4- Yuichi SUZUKI،5- Yuki ISHIHARA،6- Nobuaki SATO

[73] Owner: EISAI R&D MANAGEMENT CO., LTD., 6-10, Koishikawa 4-chome, Bunkyo-ku, Tokyo 112 - 8088, Japan

[74] Agent: Al Nami Law Firm Attorneys and Legal Advisors

  

 

  

[51]IPC:
Int. Cl.: A61K 31/437, 31/444, 31/506; A61P 25/28, 43/00; C07D 471/04 (2006.01)

[56] Cited Documents:

-WO 2008/072779 A1 (ASKA Pharmaceutical Co.,Ltd.),19 June 2008
-WO 2010/101230 A1 (Astellas Pharma Inc.),10 September 2010
-JP 2011-516454 A. (Boehringer IngelheimInternational GmbH),26 May 2011
-WO 2007/032466 A1 (ASKA Pharmaceutical Co.,Ltd.),22 March 2007
-WO 2012/033144 A1 (Astellas Pharma Inc.),15 March 2012 .
 
Examiner: PH. Nada A. AlShamrani

[54] PYRAZOLOQUINOLINE DERIVATIVES
[57] Abstract: ABSTRACTA compound or pharmacologically acceptable salt thereof represented by the formula (I) exhibits PDE9 inhibitory action and is useful as a cognitive impairment improving agent in Alzheimer's disease.
No. of claims: 19     No. of figures: 1


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.